133 related articles for article (PubMed ID: 33785258)
21. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
22. Depletion of pro-inflammatory CD161(+) double negative (CD3(+)CD4(-)CD8(-)) T cells in AIDS patients is ameliorated by expansion of the γδ T cell population.
Singleterry WL; Henderson H; Cruse JM
Exp Mol Pathol; 2012 Feb; 92(1):155-9. PubMed ID: 22100877
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
24. Potentiating Vγ9Vδ2 T cell proliferation and assessing their cytotoxicity towards adherent cancer cells at the single cell level.
Liu C; Skorupinska-Tudek K; Eriksson SG; Parmryd I
Biol Open; 2022 Feb; 11(1):. PubMed ID: 34994391
[TBL] [Abstract][Full Text] [Related]
25. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
[TBL] [Abstract][Full Text] [Related]
26. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma.
Sicard H; Al Saati T; Delsol G; Fournié JJ
Mol Med; 2001 Oct; 7(10):711-22. PubMed ID: 11713370
[TBL] [Abstract][Full Text] [Related]
27. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
Lafont V; Liautard J; Liautard JP; Favero J
J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
[TBL] [Abstract][Full Text] [Related]
28. Central memory Vgamma9Vdelta2 T lymphocytes primed and expanded by bacillus Calmette-Guérin-infected dendritic cells kill mycobacterial-infected monocytes.
Martino A; Casetti R; Sacchi A; Poccia F
J Immunol; 2007 Sep; 179(5):3057-64. PubMed ID: 17709520
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Kakimi K; Matsushita H; Masuzawa K; Karasaki T; Kobayashi Y; Nagaoka K; Hosoi A; Ikemura S; Kitano K; Kawada I; Manabe T; Takehara T; Ebisudani T; Nagayama K; Nakamura Y; Suzuki R; Yasuda H; Sato M; Soejima K; Nakajima J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948652
[TBL] [Abstract][Full Text] [Related]
30. Vγ9Vδ2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count.
Casetti R; De Simone G; Sacchi A; Rinaldi A; Viola D; Agrati C; Bordoni V; Cimini E; Tumino N; Besi F; Martini F
PLoS One; 2015; 10(7):e0132291. PubMed ID: 26161861
[TBL] [Abstract][Full Text] [Related]
31. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
[TBL] [Abstract][Full Text] [Related]
33. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
34. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
36. Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing.
Wu Z; Lamao Q; Gu M; Jin X; Liu Y; Tian F; Yu Y; Yuan P; Gao S; Fulford TS; Uldrich AP; Wong CC; Wei W
Cell Mol Immunol; 2024 Apr; 21(4):362-373. PubMed ID: 38374404
[TBL] [Abstract][Full Text] [Related]
37. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
38. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
[TBL] [Abstract][Full Text] [Related]
39. Bacterial outer-membrane vesicles promote Vγ9Vδ2 T cell oncolytic activity.
Firth J; Sun J; George V; Huang JD; Bajaj-Elliott M; Gustafsson K
Front Immunol; 2023; 14():1198996. PubMed ID: 37529036
[TBL] [Abstract][Full Text] [Related]
40. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
